2Soloway MS.Intravesical therapy for baldder cancer. Urologic Clinics of North America . 1980
3Huland E,Huland H.Local continuous high dose interleukin 2:a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Research . 1989
4Yamauchi N,Kuriyama H,Watamake N,et al.Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cell in vitro. Cancer Research . 1989
5Pagano F,Bassi P,Milani C,et al.BCG in superficial bladder cancer:a review of phase Ⅲ European trials. European Urology . 1992
6Saraya KA,Balkwill FR.Temporal sequence and cellular origin of interleukin—2 stimulated cytokine gene expression. British Journal of Cancer . 1993
7Watamabe N,Yamachi N,Neda H,et al.Enhancement of lysosomal enzyme activity by recombinant human tumor nereosis factor and its role in tumor cell killing in vitro. Japanese Journal of Cancer Research . 1992
8Whteside TL,Letessier E,Hirabayashi H,et al.Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell cardinoma of the head and neck. Cancer Research . 1993
9Pizza G,Severini G,Menniti D,et al.Tumor regfession after intralesional injection of interleukin 2(IL—2)in bladder cancer preliminary report. International Journal of Cancer . 1984
10Schwaibold H,Huland E,Heinzer H,et al.Toxicity of local,continuous,high dose bladder perfusion with interieukin—2 in patients with advanced transitional cell carcinoma (TCC).Long—term experience with cyclic permanent treatment schedules and recombinant and natural interleukin—2. Journal d Urologie . 1993
